Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin
combination in patients with squamous cell carcinoma of head and neck (SCCHN).
Phase:
Phase 1
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center